Global Kidney Cancer Drugs Sales Market Report 2021

1 Kidney Cancer Drugs Market Overview

• 1.1 Kidney Cancer Drugs Product Scope
• 1.2 Kidney Cancer Drugs Segment by Type
  • 1.2.1 Global Kidney Cancer Drugs Sales by Type (2016 & 2021 & 2027)
  • 1.2.2 Angiogenesis Inhibitors
  • 1.2.3 mTOR Inhibitors
  • 1.2.4 Monoclonal Antibodies
  • 1.2.5 Cytokine Immunotherapy (IL-2)
• 1.3 Kidney Cancer Drugs Segment by Application
  • 1.3.1 Global Kidney Cancer Drugs Sales Comparison by Application (2016 & 2021 & 2027)
  • 1.3.2 Renal Cell Carcinoma (RCC)
  • 1.3.3 Transitional Cell Carcinoma (TCC)
• 1.4 Kidney Cancer Drugs Market Estimates and Forecasts (2016-2027)
  • 1.4.1 Global Kidney Cancer Drugs Market Size in Value Growth Rate (2016-2027)
  • 1.4.2 Global Kidney Cancer Drugs Market Size in Volume Growth Rate (2016-2027)
  • 1.4.3 Global Kidney Cancer Drugs Price Trends (2016-2027)

2 Kidney Cancer Drugs Estimates and Forecasts by Region

• 2.1 Global Kidney Cancer Drugs Market Size by Region: 2016 VS 2021 VS 2027
• 2.2 Global Kidney Cancer Drugs Retrospective Market Scenario by Region (2016-2021)
  • 2.2.1 Global Kidney Cancer Drugs Sales Market Share by Region (2016-2021)
  • 2.2.2 Global Kidney Cancer Drugs Revenue Market Share by Region (2016-2021)
• 2.3 Global Kidney Cancer Drugs Market Estimates and Forecasts by Region (2022-2027)
  • 2.3.1 Global Kidney Cancer Drugs Sales Estimates and Forecasts by Region (2022-2027)
  • 2.3.2 Global Kidney Cancer Drugs Revenue Forecast by Region (2022-2027)
• 2.4 Geographic Market Analysis: Market Facts & Figures
  • 2.4.1 North America Kidney Cancer Drugs Estimates and Projections (2016-2027)
  • 2.4.2 Europe Kidney Cancer Drugs Estimates and Projections (2016-2027)
  • 2.4.3 China Kidney Cancer Drugs Estimates and Projections (2016-2027)
  • 2.4.4 Japan Kidney Cancer Drugs Estimates and Projections (2016-2027)
  • 2.4.5 Southeast Asia Kidney Cancer Drugs Estimates and Projections (2016-2027)
  • 2.4.6 India Kidney Cancer Drugs Estimates and Projections (2016-2027)

3 Global Kidney Cancer Drugs Competition Landscape by Players

• 3.1 Global Top Kidney Cancer Drugs Players by Sales (2016-2021)
• 3.2 Global Top Kidney Cancer Drugs Players by Revenue (2016-2021)
• 3.3 Global Kidney Cancer Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Kidney Cancer Drugs as of 2020)
• 3.4 Global Kidney Cancer Drugs Average Price by Company (2016-2021)
• 3.5 Manufacturers Kidney Cancer Drugs Manufacturing Sites, Area Served, Product Type
• 3.6 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Global Kidney Cancer Drugs Market Size by Type

• 4.1 Global Kidney Cancer Drugs Historic Market Review by Type (2016-2021)
  • 4.1.1 Global Kidney Cancer Drugs Sales Market Share by Type (2016-2021)
  • 4.1.2 Global Kidney Cancer Drugs Revenue Market Share by Type (2016-2021)
  • 4.1.3 Global Kidney Cancer Drugs Price by Type (2016-2021)
• 4.2 Global Kidney Cancer Drugs Market Estimates and Forecasts by Type (2022-2027)
  • 4.2.1 Global Kidney Cancer Drugs Sales Forecast by Type (2022-2027)
  • 4.2.2 Global Kidney Cancer Drugs Revenue Forecast by Type (2022-2027)
  • 4.2.3 Global Kidney Cancer Drugs Price Forecast by Type (2022-2027)

5 Global Kidney Cancer Drugs Market Size by Application

• 5.1 Global Kidney Cancer Drugs Historic Market Review by Application (2016-2021)
  • 5.1.1 Global Kidney Cancer Drugs Sales Market Share by Application (2016-2021)
  • 5.1.2 Global Kidney Cancer Drugs Revenue Market Share by Application (2016-2021)
  • 5.1.3 Global Kidney Cancer Drugs Price by Application (2016-2021)
• 5.2 Global Kidney Cancer Drugs Market Estimates and Forecasts by Application (2022-2027)
  • 5.2.1 Global Kidney Cancer Drugs Sales Forecast by Application (2022-2027)
  • 5.2.2 Global Kidney Cancer Drugs Revenue Forecast by Application (2022-2027)
  • 5.2.3 Global Kidney Cancer Drugs Price Forecast by Application (2022-2027)

6 North America Kidney Cancer Drugs Market Facts & Figures

• 6.1 North America Kidney Cancer Drugs Sales by Company
  • 6.1.1 North America Kidney Cancer Drugs Sales by Company (2016-2021)
  • 6.1.2 North America Kidney Cancer Drugs Revenue by Company (2016-2021)
• 6.2 North America Kidney Cancer Drugs Sales Breakdown by Type
  • 6.2.1 North America Kidney Cancer Drugs Sales Breakdown by Type (2016-2021)
  • 6.2.2 North America Kidney Cancer Drugs Sales Breakdown by Type (2022-2027)
• 6.3 North America Kidney Cancer Drugs Sales Breakdown by Application
  • 6.3.1 North America Kidney Cancer Drugs Sales Breakdown by Application (2016-2021)
  • 6.3.2 North America Kidney Cancer Drugs Sales Breakdown by Application (2022-2027)

7 Europe Kidney Cancer Drugs Market Facts & Figures

• 7.1 Europe Kidney Cancer Drugs Sales by Company
  • 7.1.1 Europe Kidney Cancer Drugs Sales by Company (2016-2021)
  • 7.1.2 Europe Kidney Cancer Drugs Revenue by Company (2016-2021)
• 7.2 Europe Kidney Cancer Drugs Sales Breakdown by Type
  • 7.2.1 Europe Kidney Cancer Drugs Sales Breakdown by Type (2016-2021)
  • 7.2.2 Europe Kidney Cancer Drugs Sales Breakdown by Type (2022-2027)
• 7.3 Europe Kidney Cancer Drugs Sales Breakdown by Application
  • 7.3.1 Europe 149 Sales Breakdown by Application (2016-2021)
  • 7.3.2 Europe 149 Sales Breakdown by Application (2022-2027)

8 China Kidney Cancer Drugs Market Facts & Figures

• 8.1 China Kidney Cancer Drugs Sales by Company
  • 8.1.1 China Kidney Cancer Drugs Sales by Company (2016-2021)
  • 8.1.2 China Kidney Cancer Drugs Revenue by Company (2016-2021)
• 8.2 China Kidney Cancer Drugs Sales Breakdown by Type
  • 8.2.1 China Kidney Cancer Drugs Sales Breakdown by Type (2016-2021)
  • 8.2.2 China Kidney Cancer Drugs Sales Breakdown by Type (2022-2027)
• 8.3 China Kidney Cancer Drugs Sales Breakdown by Application
  • 8.3.1 China 175 Sales Breakdown by Application (2016-2021)
  • 8.3.2 China 175 Sales Breakdown by Application (2022-2027)

9 Japan Kidney Cancer Drugs Market Facts & Figures

• 9.1 Japan Kidney Cancer Drugs Sales by Company
  • 9.1.1 Japan Kidney Cancer Drugs Sales by Company (2016-2021)
  • 9.1.2 Japan Kidney Cancer Drugs Revenue by Company (2016-2021)
• 9.2 Japan Kidney Cancer Drugs Sales Breakdown by Type
  • 9.2.1 Japan Kidney Cancer Drugs Sales Breakdown by Type (2016-2021)
  • 9.2.2 Japan Kidney Cancer Drugs Sales Breakdown by Type (2022-2027)
• 9.3 Japan Kidney Cancer Drugs Sales Breakdown by Application
  • 9.3.1 Japan Mar. Sales Breakdown by Application (2016-2021)
  • 9.3.2 Japan Mar. Sales Breakdown by Application (2022-2027)

10 Southeast Asia Kidney Cancer Drugs Market Facts & Figures

• 10.1 Southeast Asia Kidney Cancer Drugs Sales by Company
  • 10.1.1 Southeast Asia Kidney Cancer Drugs Sales by Company (2016-2021)
  • 10.1.2 Southeast Asia Kidney Cancer Drugs Revenue by Company (2016-2021)
• 10.2 Southeast Asia Kidney Cancer Drugs Sales Breakdown by Type
  • 10.2.1 Southeast Asia Kidney Cancer Drugs Sales Breakdown by Type (2016-2021)
  • 10.2.2 Southeast Asia Kidney Cancer Drugs Sales Breakdown by Type (2022-2027)
• 10.3 Southeast Asia Kidney Cancer Drugs Sales Breakdown by Application
  • 10.3.1 Southeast Asia K Units Sales Breakdown by Application (2016-2021)
  • 10.3.2 Southeast Asia K Units Sales Breakdown by Application (2022-2027)

11 India Kidney Cancer Drugs Market Facts & Figures

• 11.1 India Kidney Cancer Drugs Sales by Company
  • 11.1.1 India Kidney Cancer Drugs Sales by Company (2016-2021)
  • 11.1.2 India Kidney Cancer Drugs Revenue by Company (2016-2021)
• 11.2 India Kidney Cancer Drugs Sales Breakdown by Type
  • 11.2.1 India Kidney Cancer Drugs Sales Breakdown by Type (2016-2021)
  • 11.2.2 India Kidney Cancer Drugs Sales Breakdown by Type (2022-2027)
• 11.3 India Kidney Cancer Drugs Sales Breakdown by Application
  • 11.3.1 India Kidney Cancer Drugs Sales Breakdown by Application (2016-2021)
  • 11.3.2 India Kidney Cancer Drugs Sales Breakdown by Application (2022-2027)

12 Company Profiles and Key Figures in Kidney Cancer Drugs Business

• 12.1 Bayer
  • 12.1.1 Bayer Corporation Information
  • 12.1.2 Bayer Business Overview
  • 12.1.3 Bayer Kidney Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.1.4 Bayer Kidney Cancer Drugs Products Offered
  • 12.1.5 Bayer Recent Development
• 12.2 Roche
  • 12.2.1 Roche Corporation Information
  • 12.2.2 Roche Business Overview
  • 12.2.3 Roche Kidney Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.2.4 Roche Kidney Cancer Drugs Products Offered
  • 12.2.5 Roche Recent Development
• 12.3 GlaxoSmithKline
  • 12.3.1 GlaxoSmithKline Corporation Information
  • 12.3.2 GlaxoSmithKline Business Overview
  • 12.3.3 GlaxoSmithKline Kidney Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.3.4 GlaxoSmithKline Kidney Cancer Drugs Products Offered
  • 12.3.5 GlaxoSmithKline Recent Development
• 12.4 Novartis
  • 12.4.1 Novartis Corporation Information
  • 12.4.2 Novartis Business Overview
  • 12.4.3 Novartis Kidney Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.4.4 Novartis Kidney Cancer Drugs Products Offered
  • 12.4.5 Novartis Recent Development
• 12.5 Pfizer
  • 12.5.1 Pfizer Corporation Information
  • 12.5.2 Pfizer Business Overview
  • 12.5.3 Pfizer Kidney Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.5.4 Pfizer Kidney Cancer Drugs Products Offered
  • 12.5.5 Pfizer Recent Development
• 12.6 Abbott Laboratories
  • 12.6.1 Abbott Laboratories Corporation Information
  • 12.6.2 Abbott Laboratories Business Overview
  • 12.6.3 Abbott Laboratories Kidney Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.6.4 Abbott Laboratories Kidney Cancer Drugs Products Offered
  • 12.6.5 Abbott Laboratories Recent Development
• 12.7 Active Biotech
  • 12.7.1 Active Biotech Corporation Information
  • 12.7.2 Active Biotech Business Overview
  • 12.7.3 Active Biotech Kidney Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.7.4 Active Biotech Kidney Cancer Drugs Products Offered
  • 12.7.5 Active Biotech Recent Development
• 12.8 Amgen
  • 12.8.1 Amgen Corporation Information
  • 12.8.2 Amgen Business Overview
  • 12.8.3 Amgen Kidney Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.8.4 Amgen Kidney Cancer Drugs Products Offered
  • 12.8.5 Amgen Recent Development
• 12.9 Argos Therapeutics
  • 12.9.1 Argos Therapeutics Corporation Information
  • 12.9.2 Argos Therapeutics Business Overview
  • 12.9.3 Argos Therapeutics Kidney Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.9.4 Argos Therapeutics Kidney Cancer Drugs Products Offered
  • 12.9.5 Argos Therapeutics Recent Development
• 12.10 ArQule
  • 12.10.1 ArQule Corporation Information
  • 12.10.2 ArQule Business Overview
  • 12.10.3 ArQule Kidney Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.10.4 ArQule Kidney Cancer Drugs Products Offered
  • 12.10.5 ArQule Recent Development
• 12.11 AVEO Pharmaceuticals
  • 12.11.1 AVEO Pharmaceuticals Corporation Information
  • 12.11.2 AVEO Pharmaceuticals Business Overview
  • 12.11.3 AVEO Pharmaceuticals Kidney Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.11.4 AVEO Pharmaceuticals Kidney Cancer Drugs Products Offered
  • 12.11.5 AVEO Pharmaceuticals Recent Development
• 12.12 Bionomics
  • 12.12.1 Bionomics Corporation Information
  • 12.12.2 Bionomics Business Overview
  • 12.12.3 Bionomics Kidney Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.12.4 Bionomics Kidney Cancer Drugs Products Offered
  • 12.12.5 Bionomics Recent Development
• 12.13 Bristol-Myers Squibb
  • 12.13.1 Bristol-Myers Squibb Corporation Information
  • 12.13.2 Bristol-Myers Squibb Business Overview
  • 12.13.3 Bristol-Myers Squibb Kidney Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.13.4 Bristol-Myers Squibb Kidney Cancer Drugs Products Offered
  • 12.13.5 Bristol-Myers Squibb Recent Development
• 12.14 Cerulean Pharma
  • 12.14.1 Cerulean Pharma Corporation Information
  • 12.14.2 Cerulean Pharma Business Overview
  • 12.14.3 Cerulean Pharma Kidney Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.14.4 Cerulean Pharma Kidney Cancer Drugs Products Offered
  • 12.14.5 Cerulean Pharma Recent Development
• 12.15 Exelixis
  • 12.15.1 Exelixis Corporation Information
  • 12.15.2 Exelixis Business Overview
  • 12.15.3 Exelixis Kidney Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.15.4 Exelixis Kidney Cancer Drugs Products Offered
  • 12.15.5 Exelixis Recent Development
• 12.16 Genentech
  • 12.16.1 Genentech Corporation Information
  • 12.16.2 Genentech Business Overview
  • 12.16.3 Genentech Kidney Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.16.4 Genentech Kidney Cancer Drugs Products Offered
  • 12.16.5 Genentech Recent Development
• 12.17 immatics biotechnologies
  • 12.17.1 immatics biotechnologies Corporation Information
  • 12.17.2 immatics biotechnologies Business Overview
  • 12.17.3 immatics biotechnologies Kidney Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.17.4 immatics biotechnologies Kidney Cancer Drugs Products Offered
  • 12.17.5 immatics biotechnologies Recent Development
• 12.18 Immunicum
  • 12.18.1 Immunicum Corporation Information
  • 12.18.2 Immunicum Business Overview
  • 12.18.3 Immunicum Kidney Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.18.4 Immunicum Kidney Cancer Drugs Products Offered
  • 12.18.5 Immunicum Recent Development
• 12.19 Ono Pharmaceutical
  • 12.19.1 Ono Pharmaceutical Corporation Information
  • 12.19.2 Ono Pharmaceutical Business Overview
  • 12.19.3 Ono Pharmaceutical Kidney Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.19.4 Ono Pharmaceutical Kidney Cancer Drugs Products Offered
  • 12.19.5 Ono Pharmaceutical Recent Development
• 12.20 Onyx Therapeutics
  • 12.20.1 Onyx Therapeutics Corporation Information
  • 12.20.2 Onyx Therapeutics Business Overview
  • 12.20.3 Onyx Therapeutics Kidney Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.20.4 Onyx Therapeutics Kidney Cancer Drugs Products Offered
  • 12.20.5 Onyx Therapeutics Recent Development
• 12.21 Oxford BioMedica
  • 12.21.1 Oxford BioMedica Corporation Information
  • 12.21.2 Oxford BioMedica Business Overview
  • 12.21.3 Oxford BioMedica Kidney Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.21.4 Oxford BioMedica Kidney Cancer Drugs Products Offered
  • 12.21.5 Oxford BioMedica Recent Development
• 12.22 Prometheus Laboratories
  • 12.22.1 Prometheus Laboratories Corporation Information
  • 12.22.2 Prometheus Laboratories Business Overview
  • 12.22.3 Prometheus Laboratories Kidney Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.22.4 Prometheus Laboratories Kidney Cancer Drugs Products Offered
  • 12.22.5 Prometheus Laboratories Recent Development
• 12.23 Seattle Genetics
  • 12.23.1 Seattle Genetics Corporation Information
  • 12.23.2 Seattle Genetics Business Overview
  • 12.23.3 Seattle Genetics Kidney Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.23.4 Seattle Genetics Kidney Cancer Drugs Products Offered
  • 12.23.5 Seattle Genetics Recent Development
• 12.24 Taiwan Liposome
  • 12.24.1 Taiwan Liposome Corporation Information
  • 12.24.2 Taiwan Liposome Business Overview
  • 12.24.3 Taiwan Liposome Kidney Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.24.4 Taiwan Liposome Kidney Cancer Drugs Products Offered
  • 12.24.5 Taiwan Liposome Recent Development
• 12.25 Tracon Pharmaceuticals
  • 12.25.1 Tracon Pharmaceuticals Corporation Information
  • 12.25.2 Tracon Pharmaceuticals Business Overview
  • 12.25.3 Tracon Pharmaceuticals Kidney Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.25.4 Tracon Pharmaceuticals Kidney Cancer Drugs Products Offered
  • 12.25.5 Tracon Pharmaceuticals Recent Development
• 12.26 Wilex
  • 12.26.1 Wilex Corporation Information
  • 12.26.2 Wilex Business Overview
  • 12.26.3 Wilex Kidney Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 12.26.4 Wilex Kidney Cancer Drugs Products Offered
  • 12.26.5 Wilex Recent Development

13 Kidney Cancer Drugs Manufacturing Cost Analysis

• 13.1 Kidney Cancer Drugs Key Raw Materials Analysis
  • 13.1.1 Key Raw Materials
  • 13.1.2 Key Raw Materials Price Trend
  • 13.1.3 Key Suppliers of Raw Materials
• 13.2 Proportion of Manufacturing Cost Structure
• 13.3 Manufacturing Process Analysis of Kidney Cancer Drugs
• 13.4 Kidney Cancer Drugs Industrial Chain Analysis

14 Marketing Channel, Distributors and Customers

• 14.1 Marketing Channel
• 14.2 Kidney Cancer Drugs Distributors List
• 14.3 Kidney Cancer Drugs Customers

15 Market Dynamics

• 15.1 Kidney Cancer Drugs Market Trends
• 15.2 Kidney Cancer Drugs Drivers
• 15.3 Kidney Cancer Drugs Market Challenges
• 15.4 Kidney Cancer Drugs Market Restraints

16 Research Findings and Conclusion

17 Appendix

• 17.1 Research Methodology
  • 17.1.1 Methodology/Research Approach
  • 17.1.2 Data Source
• 17.2 Author List